CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Biogen Inc. - BIIB CFD

284.44
1.48%
2.38
Low: 284.44
High: 289.74
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 2.38
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Biogen Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 288.72
Open* 289.35
1-Year Change* 23.44%
Day's Range* 284.44 - 284.44
52 wk Range 187.16-307
Average Volume (10 days) 1.19225
Average Volume (3 months) 34.2121
Market Cap 44168.1
P/E Ratio 15.627
Shares Outstanding 144001000
Revenue 10363.2
EPS 19.6275
Dividend (Yield %) N/A
Beta 0.19571
Next Earnings Date Feb 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2022 288.72 -2.59 -0.89% 291.31 291.61 286.01
Dec 7, 2022 290.93 2.15 0.74% 288.78 293.22 286.48
Dec 6, 2022 290.08 0.84 0.29% 289.24 294.56 288.15
Dec 5, 2022 292.43 -5.09 -1.71% 297.52 297.84 289.62
Dec 2, 2022 297.69 1.94 0.66% 295.75 304.74 295.75
Dec 1, 2022 300.36 -1.82 -0.60% 302.18 305.98 298.61
Nov 30, 2022 304.67 1.13 0.37% 303.54 310.98 300.84
Nov 29, 2022 291.12 0.87 0.30% 290.25 293.54 287.96
Nov 28, 2022 291.66 -1.09 -0.37% 292.75 302.51 290.05
Nov 25, 2022 304.75 3.80 1.26% 300.95 307.19 300.95
Nov 23, 2022 303.16 -0.45 -0.15% 303.61 307.04 301.83
Nov 22, 2022 306.33 4.42 1.46% 301.91 306.64 299.43
Nov 21, 2022 301.28 0.19 0.06% 301.09 305.37 300.22
Nov 18, 2022 302.64 2.24 0.75% 300.40 303.94 299.30
Nov 17, 2022 301.80 6.90 2.34% 294.90 302.68 294.90
Nov 16, 2022 299.75 2.80 0.94% 296.95 303.21 296.95
Nov 15, 2022 299.48 1.21 0.41% 298.27 303.44 296.63
Nov 14, 2022 298.65 -1.53 -0.51% 300.18 305.00 295.26
Nov 11, 2022 289.15 -1.21 -0.42% 290.36 290.56 282.77
Nov 10, 2022 290.29 2.62 0.91% 287.67 291.51 286.46

Biogen Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 11448.8 12273.9 13452.9 14377.9 13444.6 10981.7
Revenue 11448.8 12273.9 13452.9 14377.9 13444.6 10981.7
Cost of Revenue, Total 1478.7 1630 1816.3 1955.4 1805.2 2109.7
Gross Profit 9970.1 10643.9 11636.6 12422.5 11639.4 8872
Total Operating Expense 6298.4 6929.7 7564.3 7335.3 8894.5 8141
Selling/General/Admin. Expenses, Total 1947.9 1935.5 2106.3 2357 2535 2702.4
Research & Development 1973.3 2253.6 2597.2 2272.7 3984.6 2497
Depreciation / Amortization 373.4 814.7 381.2 274 255.1 252
Interest Expense (Income) - Net Operating 10.2 112.3 185 241.6 232.9 7.2
Unusual Expense (Income) 500.1 120.9 490.6 272.7 192.2 647.3
Other Operating Expenses, Total 14.8 62.7 -12.3 -38.1 -110.5 -74.6
Operating Income 5150.4 5344.2 5888.6 7042.6 4550.1 2840.7
Interest Income (Expense), Net Non-Operating -197.4 -193.6 21.5 137.3 494.5 -1089.9
Other, Net -20 -21.8 -10.5 -54 2.9 -5.6
Net Income Before Taxes 4933 5128.8 5899.6 7125.9 5047.5 1745.2
Net Income After Taxes 3695.7 3843.7 4497.7 5967.9 4055.2 1692.7
Minority Interest 7.1 -131 -43.3 0 -59.9 -171.5
Equity In Affiliates 0 0 0 -79.4 5.3 34.9
Net Income Before Extra. Items 3702.8 3712.7 4454.4 5888.5 4000.6 1556.1
Net Income 3702.8 2539.1 4430.7 5888.5 4000.6 1556.1
Income Available to Common Excl. Extra. Items 3702.8 3712.7 4454.4 5888.5 4000.6 1556.1
Income Available to Common Incl. Extra. Items 3702.8 2539.1 4430.7 5888.5 4000.6 1556.1
Diluted Net Income 3702.8 2539.1 4430.7 5888.5 4000.6 1556.1
Diluted Weighted Average Shares 218.8 213 205.3 187.4 161.3 149.6
Diluted EPS Excluding Extraordinary Items 16.9232 17.4305 21.697 31.4221 24.8022 10.4017
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS 18.6356 17.9971 23.6491 32.6408 25.851 14.6021
Total Extraordinary Items -1173.6 -23.7
Dilution Adjustment 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 2694 2775 2778.9 2733.8 2531.8
Revenue 2694 2775 2778.9 2733.8 2531.8
Cost of Revenue, Total 478.1 459.7 511.8 660.1 753.9
Gross Profit 2215.9 2315.3 2267.1 2073.7 1777.9
Total Operating Expense 1720.1 2289.3 1984.9 2146.7 1921.1
Selling/General/Admin. Expenses, Total 595 637.3 654.1 787.9 634.9
Research & Development 514.2 585.1 702.4 699.5 551.7
Depreciation / Amortization 53.8 62.5 67.6 68.1 66.9
Interest Expense (Income) - Net Operating 68.5 -15.2 21.2 -67.3 -117.3
Unusual Expense (Income) 44.3 559.6 43.4 0 38.1
Other Operating Expenses, Total -33.8 0.3 -15.6 -1.6 -7.1
Operating Income 973.9 485.7 794 587.1 610.7
Interest Income (Expense), Net Non-Operating -507 99.4 -501.9 -180.5 -262.6
Other, Net 0.1 -3 -1 -1.6 -0.7
Net Income Before Taxes 467 582.1 291.1 405 347.4
Net Income After Taxes 422.8 991.2 317 -38.2 221.8
Minority Interest 5.6 -577 11.1 388.7 85.3
Equity In Affiliates -18.2 34.3 1.1 17.7 -3.3
Net Income Before Extra. Items 410.2 448.5 329.2 368.2 303.8
Net Income 410.2 448.5 329.2 368.2 303.8
Income Available to Common Excl. Extra. Items 410.2 448.5 329.2 368.2 303.8
Income Available to Common Incl. Extra. Items 410.2 448.5 329.2 368.2 303.8
Diluted Net Income 410.2 448.5 329.2 368.2 303.8
Diluted Weighted Average Shares 152.3 150.1 148.6 147.5 147.6
Diluted EPS Excluding Extraordinary Items 2.69337 2.98801 2.21534 2.49627 2.05827
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 2.95671 5.4533 2.40518 2.49627 2.22307
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 8732.2 7873.3 7640.9 8381.8 6887.1 7856.5
Cash and Short Term Investments 4895.1 3689 3538 4475.9 2610.1 3802.5
Cash & Equivalents 2326.5 1573.8 1224.6 2913.7 1331.2 2261.4
Short Term Investments 2568.6 2115.2 2313.4 1562.2 1278.9 1541.1
Total Receivables, Net 1742.2 2319.6 2485.4 2470.7 2327.3 1961.7
Accounts Receivable - Trade, Net 1742.2 2319.6 2485.4 2470.7 2327.3 1961.7
Total Inventory 1001.6 902.5 929.9 804.2 1068.6 1351.5
Prepaid Expenses 817 657.6
Other Current Assets, Total 276.3 304.6 687.6 631 881.1 740.8
Total Assets 22876.8 23652.6 25288.9 27234.3 24618.9 23877.3
Property/Plant/Equipment, Total - Net 2501.8 3182.4 3601.2 3674.3 3844.8 3791.8
Property/Plant/Equipment, Total - Gross 3941.1 4741.5 5398.6 5265.2 5627.1 5798.4
Accumulated Depreciation, Total -1439.3 -1559.1 -1797.4 -1590.9 -1782.3 -2006.6
Goodwill, Net 3669.3 4632.5 5706.4 5757.8 5762.1 5761.1
Intangibles, Net 3808.3 3879.6 3120 3527.4 3084.3 2221.3
Long Term Investments 4158.6 4055.5 3038.5 2653.9 3671.1 2831.5
Other Long Term Assets, Total 6.6 29.3 2181.9 3239.1 1369.5 1415.1
Total Current Liabilities 3419.9 3368.2 3295.2 4863.8 3742.2 4298.2
Accounts Payable 279.8 395.5 370.5 530.8 454.9 589.2
Accrued Expenses 1506.1 1236.1 1545.5 1682.7 1716.1 1471
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4.7 3.2 0 1495.8 0 999.1
Other Current Liabilities, Total 1629.3 1733.4 1379.2 1154.5 1571.2 1238.9
Total Liabilities 10736.7 11039.8 12249.3 13891.1 13918.6 12981.1
Total Long Term Debt 6512.7 5935 5936.5 4459 7426.2 6274
Long Term Debt 6496.3 5935 5936.5 4459 7426.2 6274
Capital Lease Obligations 16.4 0
Deferred Income Tax 93.1 122.6 1636.2 2810.8 1032.8 694.5
Minority Interest -11.5 -14.7 -8 -4.1 -14.2 63.5
Other Liabilities, Total 722.5 1628.7 1389.4 1761.6 1731.6 1650.9
Total Equity 12140.1 12612.8 13039.6 13343.2 10700.3 10896.2
Common Stock 0.1 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 0 97.8 0 0 0 68.2
Retained Earnings (Accumulated Deficit) 15071.6 15810.4 16257 16455.4 13976.3 13911.7
Treasury Stock - Common -2611.7 -2977.1 -2977.1 -2977.1 -2977.1 -2977.1
Unrealized Gain (Loss) -10.8 -1.6 -4 4.2 1.4 -2.2
Other Equity, Total -309.1 -316.8 -236.4 -139.4 -300.4 -104.5
Total Liabilities & Shareholders’ Equity 22876.8 23652.6 25288.9 27234.3 24618.9 23877.3
Total Common Shares Outstanding 215.9 211.5 197.2 174.2 152.4 147
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 6719.5 7183.7 7162.3 7856.5 7915.9
Cash and Short Term Investments 2537.5 3050.8 2955.1 3802.5 3751.7
Cash & Equivalents 1217.5 1742 1541.8 2261.4 1749.3
Short Term Investments 1320 1308.8 1413.3 1541.1 2002.4
Total Receivables, Net 2224.1 2110.2 2123 1961.7 2021.4
Accounts Receivable - Trade, Net 2224.1 2110.2 2123 1961.7 2021.4
Total Inventory 1171.8 1254.8 1347.9 1351.5 1215.4
Other Current Assets, Total 786.1 767.9 736.3 740.8 927.4
Total Assets 23854.7 24470.4 23806.7 23877.3 23614.4
Property/Plant/Equipment, Total - Net 3852.8 3844.7 3799.8 3791.8 3731.8
Property/Plant/Equipment, Total - Gross 5265.9 5322.5 5354.9 5423 5454.8
Accumulated Depreciation, Total -1827.6 -1880.3 -1944.2 -2006.6 -2082
Goodwill, Net 5763.1 5763.9 5760.5 5761.1 5758
Intangibles, Net 2988.1 2385 2286.8 2221.3 2150.8
Long Term Investments 3244.9 3443.2 2986.9 2831.5 2769.1
Other Long Term Assets, Total 1286.3 1849.9 1810.4 1415.1 1288.8
Total Current Liabilities 3165.8 3347.2 4211.6 4298.2 3946.6
Accounts Payable 430.4 375.3 427.9 589.2 398.7
Accrued Expenses 1501.5 1524.9 1520.5 1471 1253.7
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1233.9 1447 1264.4 1238.9 1294.7
Total Liabilities 13172.5 13718.5 13376.8 12981.1 12372.1
Total Long Term Debt 7267.2 7269.2 6272.3 6274 6275.7
Long Term Debt 7267.2 7269.2 6272.3 6274 6275.7
Deferred Income Tax 966.7 918.9 774.7 694.5 571.2
Minority Interest -19 462.9 451.8 63.5 -21.6
Other Liabilities, Total 1791.8 1720.3 1666.4 1650.9 1600.2
Total Equity 10682.2 10751.9 10429.9 10896.2 11242.3
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 0 0 0 68.2 119
Retained Earnings (Accumulated Deficit) 13833.5 13900.7 13543.5 13911.7 14215.5
Treasury Stock - Common -2977.1 -2977.1 -2977.1 -2977.1 -2977.1
Unrealized Gain (Loss) 0.6 0.1 0 -2.2 -11.9
Other Equity, Total -174.9 -171.9 -136.6 -104.5 -103.3
Total Liabilities & Shareholders’ Equity 23854.7 24470.4 23806.7 23877.3 23614.4
Total Common Shares Outstanding 150.6 149.1 146.9 147 147.5
Current Port. of LT Debt/Capital Leases 998.8 999.1 999.5
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 3695.7 2670.1 4474 5888.5 4060.5 1727.6
Cash From Operating Activities 4587.2 4551 6187.7 7078.6 4229.8 3639.9
Cash From Operating Activities 682.7 1081 1016.6 680.6 457.2 487.7
Deferred Taxes -175 91.7 108.3 67.1 149 -426.8
Non-Cash Items 258.6 472.8 188.6 243.1 -249.7 1996.9
Cash Taxes Paid 1642.2 1066.4 1007.1 1064.5 906.7 247.9
Cash Interest Paid 281.2 281.7 243.2 244.2 272.7 280.8
Changes in Working Capital 125.2 235.4 400.2 199.3 -187.2 -145.5
Cash From Investing Activities -2484.8 -2963.1 -2046.3 470.5 -608.6 -563.7
Capital Expenditures -727.7 -1962.8 -886.1 -669.5 -551.8 -294.9
Other Investing Cash Flow Items, Total -1757.1 -1000.3 -1160.2 1140 -56.8 -268.8
Cash From Financing Activities -1052.6 -2380 -4472 -5860.4 -5272.7 -2086.2
Financing Cash Flow Items -49.9 -453.7 -116.2 7.9 -61 -116.2
Issuance (Retirement) of Stock, Net -1000 -1365.4 -4352.6 -5868.3 -6679.1 -1800
Issuance (Retirement) of Debt, Net -2.7 -560.9 -3.2 0 1467.4 -170
Foreign Exchange Effects -31.3 39.4 -18.6 0.4 69 -59.8
Net Change in Cash 1018.5 -752.7 -349.2 1689.1 -1582.5 930.2
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 404.6 1430.1 1748.1 1727.6 218.5
Cash From Operating Activities 769 1996.3 2801.6 3639.9 161.8
Cash From Operating Activities 102.3 219.8 353 487.7 143.1
Deferred Taxes -15 -622.8 -750.1 -426.8 1
Non-Cash Items 608 1074.4 1672.3 1996.9 579.7
Changes in Working Capital -330.9 -105.2 -221.7 -145.5 -780.5
Cash From Investing Activities -64.7 -217.4 -451 -563.7 -648
Capital Expenditures -92.6 -164.5 -226.4 -294.9 -57.9
Other Investing Cash Flow Items, Total 27.9 -52.9 -224.6 -268.8 -590.1
Cash From Financing Activities -785 -1349.5 -2096 -2086.2 -16.5
Financing Cash Flow Items -15.7 -129.5 -126 -116.2 -16.5
Issuance (Retirement) of Stock, Net -600 -1050 -1800 -1800 0
Issuance (Retirement) of Debt, Net -169.3 -170 -170 -170 0
Foreign Exchange Effects -33 -18.6 -44 -59.8 -9.4
Net Change in Cash -113.7 410.8 210.6 930.2 -512.1
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PRIMECAP Management Company Investment Advisor 10.9316 15741715 15189 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.2263 11846004 55137 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.7904 8338271 -108904 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.7884 6895357 18476 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 3.5664 5135617 -1151108 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.2913 3299475 53952 2022-09-30 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 1.3025 1875640 -91570 2022-09-30 LOW
Point72 Asset Management, L.P. Hedge Fund 1.1653 1677982 1222182 2022-09-30 HIGH
BlackRock Asset Management Ireland Limited Investment Advisor 1.1106 1599279 6431 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.08 1555205 -66806 2021-12-31 LOW
D. E. Shaw & Co., L.P. Hedge Fund 1.0662 1535315 179461 2022-09-30 MED
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9927 1429499 -26471 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.9842 1417210 408948 2022-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.9569 1377967 -304458 2022-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.9466 1363053 112599 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.9333 1344024 313093 2022-09-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 0.9241 1330783 -211894 2022-09-30 LOW
Renaissance Technologies LLC Hedge Fund 0.8017 1154507 -391500 2022-09-30 HIGH
JP Morgan Asset Management Investment Advisor 0.7732 1113464 88994 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 0.7149 1029538 -210842 2022-09-30 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
480000+

Traders

75000+

Active clients monthly

$52000000+

Monthly investing volume

$34000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Biogen Company profile

Biogen Inc. (BIIB) is a biotechnology company in the field of neurological and neurodegenerative diseases. 

Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen has devoted its scientific research to defeating neurological diseases, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). 

With the aid of some of the world’s leading neuroscientists and neurologists, Biogen has sought treatments against common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP). 

The use of advanced technologies and engineering skills has enabled Biogen to bring effective medicines to the market. The company’s products include SPINRAZA for the treatment of SMA; TECFIDERA, AVONEX, FAMPYRA, VUMERITY and TYSABRI for multiple sclerosis; ADUHELM for Alzheimer’s disease; and FUMADERM for the treatment of severe plaque psoriasis.

Biogen has made an agreement with Genentech, a member of the Roche Group for business and financial rights, with respect to RITUXAN, GAZYVA and OCREVUS. It’s constantly looking at ways to improve its research and development to compete against other biotech giants like Pfizer Inc (PFE), Johnson & Johnson (JNJ) and Amgen (AMGN). 

Biogen went public in September 1991. It trades on the Nasqaq under the ticker ‘BIIB’.

Industry: Biopharmaceuticals

225 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

People also watch

BTC/USD

17,179.20 Price
-0.220% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

XRP/USD

0.39 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00321

US100

11,547.10 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 3.0

Oil - Crude

71.65 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee -0.0013%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading